Overview of Ciplar - LA

Property	Description
Active Ingredient	Propranolol hydrochloride (INN)
Form	Oral Tablet (Extended-Release/Long-Acting)
Pharmacological Class	Nonselective Beta-Adrenergic Receptor Blocking Agent
General Purpose	Provides continuous, round-the-clock cardiovascular stabilization
Origin/Status	Synthetic, Prescription-only (Cipla Ltd. brand)

Ciplar-LA: Identity and Pharmacological Class

Ciplar-LA is a brand-name, prescription-only medicine from the manufacturer Cipla Ltd. that contains the active ingredient Propranolol hydrochloride. This substance is classified as a Nonselective Beta-Adrenergic Receptor Blocking Agent, commonly referred to as a beta-blocker. Propranolol is a synthetic, single-entity compound, distinguished by its nonselective action which targets both beta1 and beta2 receptors across various tissues. This broad mechanism supports the medicine's general purpose of regulating the body's sympathetic response to stress hormones, a role clinically recognized for its use in cardiovascular stabilization.

Long-Acting (LA) Formulation and General Purpose

The distinguishing characteristic of this preparation is the suffix 'LA', signifying a Long-Acting or Extended-Release oral tablet. This design is crucial because the immediate-release form of Propranolol requires multiple daily doses to maintain effectiveness, while the LA formulation ensures stable drug levels. The sustained-release function of Ciplar-LA ensures that the active ingredient is delivered continuously over a 24-hour cycle. The general purpose of this design is to provide a reliable, round-the-clock stabilizing effect that helps to moderate and regulate the function of the circulatory system without interruption.

Composition and Unique Characteristics

The tablet's composition pairs the active ingredient, Propranolol hydrochloride, with specialized solid oral pharmaceutical excipients and polymer matrix agents. These agents form the unique base/vehicle that physically controls the rate of drug release, thereby creating the extended-release system that distinguishes this preparation. This specific design is engineered to achieve therapeutic equivalence to multiple immediate-release doses, ensuring that the patient receives the necessary effect with the convenience of once-daily administration.

Regulatory References

Propranolol (Cardiovascular): MedlinePlus Drug Information

What side effects are possible with Ciplar - LA?

Possible Side Effects and Safety Information

The safety profile of Ciplar-LA, which contains Propranolol hydrochloride, is formally classified by regulatory authorities (such as the FDA and EMA) into categories based on frequency and the physiological systems affected.

Adverse Reaction Classification

Adverse reactions are grouped by System-Organ Class (SOC) and officially reported frequency:

Classification	Examples of Documented Effects
Common	Bradycardia (slow heart rate), fatigue, cold extremities, sleep disturbances (including nightmares).
Uncommon	Gastrointestinal disturbances (e.g., nausea, vomiting, diarrhoea).
Rare	Dizziness, hallucinations, mood changes, confusion, visual disturbances, bronchospasm, and blood disorders like thrombocytopaenia.

Serious adverse reactions explicitly documented in regulatory labeling include new or worsening heart failure, heart block, and severe cutaneous reactions (e.g., Stevens-Johnson Syndrome). Of critical importance is the risk of exacerbation of angina and myocardial infarction associated with abrupt cessation of therapy in patients with ischemic heart disease.

Safety Constraints and Special Populations

Safety-related restrictions formally listed in official documents include contraindications for conditions such as cardiogenic shock, sinus bradycardia or greater than first-degree heart block (without a pacemaker), and bronchial asthma or a history of bronchospasm.

Population-specific safety considerations address patients with hepatic or renal impairment, who may experience increased drug exposure, requiring caution. For patients with Diabetes Mellitus, the regulatory labels note that beta-blockade may mask certain clinical signs of acute hypoglycemia, such as a rapid heart rate.

This regulatory framework strictly defines the documented risks, distinguishing between common, expected effects and rare, severe outcomes, thereby outlining the medication's formal safety boundaries and necessary use restrictions.

Overdose and Emergency Response

Suspected overdose with Ciplar-LA (Propranolol hydrochloride) requires immediate medical attention. Regulatory documents specify that the drug's extended-release (LA) formulation may delay the onset of severe toxicity, often necessitating extended hospital observation.

Documented Manifestations and Severe Outcomes

Overdose may result in severe clinical manifestations due to excessive beta-blockade, primarily affecting the cardiovascular and central nervous systems. Documented presentations include severe bradycardia (slow heart rate), profound hypotension (low blood pressure), and the potential for cardiogenic shock or cardiac arrest. CNS effects like lethargy, confusion, and possibly convulsions or coma are also officially noted. Additionally, an overdose is associated with the risk of severe hypoglycemia (low blood sugar), particularly in pediatric patients.

Required Emergency Action and Management

In all cases of suspected overdose, it is mandated to seek immediate medical attention by contacting emergency services. Emergency medical care is required when life-threatening symptoms such as cardiovascular collapse, profound unconsciousness, or respiratory distress are present. Management described in official documents focuses on symptomatic and supportive treatment, including the use of specific interventions such as glucagon to counteract severe myocardial depression, along with continuous ECG and blood glucose monitoring.

Therapeutic Uses of Ciplar - LA

Ciplar-LA is applied across domains where additional symptomatic support is needed, primarily focusing on conditions presenting with systemic or localized discomfort. This medication is considered relevant for easing symptoms related to physical discomfort in several therapeutic areas.

It is commonly used to help manage high blood pressure (hypertension) and reduce the symptom burden of angina pectoris (chest pain), and it may contribute to overall cardiovascular stability. Beyond heart conditions, it is applied as a preventive agent to decrease the frequency and severity of migraine headaches, and it helps manage symptoms of increased neurological or muscular activity associated with essential tremor.

“This medicine is commonly used for managing symptoms that interfere with daily functioning and is applied in scenarios where additional management of discomfort is required.”

It is often used when supportive symptom management is appropriate for conditions involving recurrent or episodic manifestations. It provides support that helps ease the overall symptom burden and assists with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Episodic Discomfort Ciplar-LA is relevant in contexts involving heightened systemic burden, such as addressing palpitations and rapid heart rate seen with arrhythmias or the physical manifestations of thyrotoxicosis (overactive thyroid).

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ciplar - LA — official regulatory information

Eligibility Scope

The medicine is approved for use in the adult population who do not have any contraindications listed in the product labeling. Use is not recommended in the pediatric population (children and adolescents under 18 years) as safety and efficacy have not been established.

Populations for whom use is contraindicated

Use is absolutely prohibited (contraindicated) for individuals with the following conditions, as stated in regulatory prescribing information:

Cardiogenic shock or decompensated heart failure.
Bronchial asthma or a history of bronchospasm.
Sinus bradycardia and heart block greater than first-degree (unless a pacemaker is present).
Severe hypotension.
Metabolic acidosis or patients prone to hypoglycemia (e.g., after prolonged fasting).
Known hypersensitivity to propranolol.

Condition-specific eligibility rules

Use requires caution in patients with hepatic (liver) or renal (kidney) impairment due to the risk of reduced drug clearance. Caution is also advised for diabetes mellitus patients, as the medicine can mask signs of acute hypoglycemia. For pregnancy, use is permitted only if the potential benefit justifies the potential risk to the fetus.

Connection to the overall eligibility profile

Official regulatory documents define eligibility by establishing who is allowed (adults without contraindications), who is prohibited (patients with absolute contraindications), and for whom use is conditional (e.g., those with organ impairment), solely based on mandatory labeling rules.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Propranolol (the active ingredient in Ciplar-LA) is formally documented across two main categories: Pharmacokinetic (PK) and Pharmacodynamic (PD). This profile defines specific restrictions for co-administration, as stated in regulatory prescribing information.

Official Interaction Restrictions

Classification	Official Regulatory Statement
Contraindicated Combinations	Co-administration with certain Non-dihydropyridine Calcium Channel Blockers (Verapamil, Diltiazem) is contraindicated by some regulatory labels due to the high risk of severe cardiac depression, hypotension, and bradycardia. Intravenous administration of either agent should be separated by at least 48 hours from the discontinuation of the other.
Pharmacokinetic Modulators	Substances that inhibit enzymes CYP2D6, CYP1A2, and CYP2C19 (e.g., Fluoxetine, Cimetidine) can increase exposure to Propranolol. Conversely, CYP Inducers (e.g., Rifampin) decrease plasma concentrations and increase clearance, potentially reducing efficacy. Bile acid sequestrants, such as Cholestyramine, significantly reduce Propranolol levels.
Pharmacodynamic Effects	Additive effects on the heart are documented with drugs like Digoxin and Clonidine, increasing the potential for significant bradycardia. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may antagonize the antihypertensive effect of Propranolol. Triptans, such as Rizatriptan, show increased exposure when co-administered.
Substance Interactions	Ethanol (alcohol) and cigarette smoking are documented to reduce the plasma concentrations of Propranolol via hepatic metabolism induction.

Population-Specific Notes

Patients with hepatic impairment are at a greater risk for increased Propranolol exposure. For diabetic patients, the drug may mask the tachycardia symptom of hypoglycemia and prolong the hypoglycemic response to insulin or other agents.

Mechanism of Action

Ciplar-LA (propranolol) functions as a non-selective beta-adrenergic receptor antagonist. It exerts its primary pharmacodynamic action by competitively blocking the effects of the catecholamines adrenaline and noradrenaline on beta1 and beta2 receptors across the body.

Cardiac Adrenergic Receptor Blockade

The molecule engages beta1-adrenergic receptors, predominantly located in myocardial tissue. Competitive antagonism prevents the typical sympathetic nervous system response, modifying early molecular signaling steps within the heart muscle. This engagement results in modified chronotropic (rate) and inotropic (force) responses.

Central Sympathetic Modulation

Propranolol is lipophilic and crosses the blood-brain barrier, allowing it to influence central adrenergic receptor signaling pathways. It modulates noradrenergic activity in brain regions, resulting in the modulation of signaling sequences associated with heightened autonomic responses.

Vascular and Smooth Muscle Receptor Interaction

Antagonism of peripheral beta2-adrenergic receptors occurs in tissues like the smooth muscle of blood vessels and bronchi. By preventing receptor stimulation, the drug alters the responsiveness of these tissues to adrenergic mediators, influencing baseline vascular and bronchial tone.

Dosage and Administration Information

How Ciplar - LA is Used: Official Administration Guidelines

Ciplar-LA (propranolol hydrochloride extended-release) is strictly intended for oral administration and is taken as a long-acting capsule or tablet once daily. To ensure the controlled release of the active ingredient over a 24-hour period, the capsule or tablet must be swallowed whole and should never be crushed, chewed, or divided. This procedural constraint is essential for maintaining the intended drug delivery profile.

The standard labeled dosing regimen is designed for long-term maintenance therapy. Treatment typically commences with an initial dose of 80 mg once daily. The dose is then subject to adjustment, or titration, which is carried out gradually over periods of several weeks to achieve the desired effect, with maintenance doses often ranging between 80 mg and 320 mg once daily.

For proper use, the medicine should be taken consistently with respect to food intake, meaning the patient should adhere to taking it either always with food or always on an empty stomach. While many formulations permit morning or evening dosing, some specific extended-release products may instruct administration at bedtime.

Procedural rules also govern treatment modification. For older adults, the official guidance suggests initiating treatment at the lower end of the dosing range and titrating cautiously. Furthermore, if therapy is to be stopped, the dose must be reduced gradually over a period of time, as abrupt discontinuation is a known procedural restriction for this class of medicine. The extended-release formulation is also generally not intended for use in pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ciplar - LA

Evidence for Use in High Blood Pressure (Hypertension)

Research includes Randomized Controlled Trials (RCTs) and meta-analyses that examined changes in blood pressure, heart rate, and related hemodynamic measurements over a 24-hour period. Studies included adults, with some enrolling patients who also had coexisting high-risk factors like diabetes. Findings describe patterns observed where blood pressure measurements changed. Comparisons suggest the extended-release formulation provides a more consistent concentration of the medicine. Certainty remains low when comparing this medicine to some other drug classes regarding the protective effect against stroke.

Evidence for Use in Migraine Headaches (Prophylaxis)

Evidence relies on RCTs and systematic reviews that examined the measured effect on the frequency and severity of migraine headache days. Researchers measured headache frequency and severity in both adult and pediatric patient groups. Findings describe patterns observed where the measured number of monthly migraine headache days differed between the study groups. It is not yet clear whether the precise biological process for the observed change in migraine frequency is fully established in research.

Evidence for Use in Chronic Stable Angina Pectoris (Chest Pain)

Clinical studies explored the medicine's activity in adults with stable chest pain by assessing exercise tolerance and the time it took for chest pain to begin during stress testing. Reports describe patterns observed where the measured duration of exercise before chest discomfort differed in subjects. The extended-release formulation was reported to sustain the change in exercise response consistently across the 24-hour dosing interval.

Evidence for Use in Essential Tremor

Evidence relies on Systematic Reviews and Meta-analyses that investigated measured changes in tremor severity and improvements in functional abilities. Studies report how symptoms evolved by describing changes in severity scores for limb tremors in some subjects. Data indicate patterns related to a proportion of patients who were observed to have no measured change in tremor severity, and research describes limited measured effect for axial tremors.

Long-Term Studies and Follow-up Duration

The research base includes intermediate-term studies and long-term systematic reviews for cardiovascular outcomes. However, long-term effects are not fully established for all indications, and follow-up durations were limited in many of the core studies.

Evidence in Special Populations

Research has been studied for older adults and, separately, pediatric patients. However, data for certain groups remain insufficient; for instance, comparative evidence is lacking for certain comorbidity groups.

What is Still Uncertain About Ciplar - LA Research

Research highlights that what is still uncertain includes the precise biological mechanism for observed effects on migraine and tremor. Additionally, evidence quality varies across studies when comparing this medicine against other therapies.

Frequently Asked Questions (FAQ)

Common questions about Ciplar - LA (FAQ)

Q: What is the difference between Ciplar and Ciplar - LA?

The active ingredient in both is propranolol, but they differ in how they release the medicine. Official product information describes the Ciplar - LA (long-acting) formulation as having a special design to release the medicine slowly over a full 24 hours. This design allows the LA version to be taken only once daily, while the standard form is generally taken multiple times per day to maintain its effect.

Q: How quickly does Ciplar - LA start to work for physical symptoms?

Regulatory information indicates that the extended-release formulation is designed for a consistent, long-term effect rather than immediate relief. Pharmacokinetic studies show that the maximum concentration in the blood is typically reached in about six hours after administration. Effects on heart rate usually begin to be observed within 1 to 2 hours after a dose.

Q: Does Ciplar - LA cause weight gain?

Weight gain itself is not documented as a common side effect of this medicine in official regulatory sources. However, rapid or sudden weight gain is a documented symptom of worsening heart failure, which is listed as a serious adverse reaction associated with this class of medication.

Q: What should be done if a dose of Ciplar - LA is missed?

Official patient instructions describe a procedure for handling a missed dose. If a dose is remembered, the guidance is to take it, unless the time is closer to the next scheduled dose. If it is closer to the next dose, the official guidance suggests skipping the missed dose and returning to the regular schedule. Regulatory guidance warns against taking two doses at the same time.

Q: Is Ciplar - LA a controlled substance?

Official government drug authorities, such as the U.S. Drug Enforcement Administration, classify medications based on their potential for abuse. Propranolol, the active ingredient in Ciplar - LA, is classified as a prescription-only drug but is not designated as a controlled substance.

Q: Does Ciplar - LA cause hair loss?

Hair thinning, also known as alopecia, has been reported in post-marketing surveillance reports as a possible side effect of this medication. Official sources classify these types of reports as generally rare.

Q: Can taking Ciplar - LA affect my ability to drive?

Official regulatory warnings state that this medicine may cause side effects such as dizziness or drowsiness. The official warnings note that due to this potential impact on mental alertness and coordination, caution should be exercised when operating complex machinery or driving.

Q: Is Ciplar - LA a blood thinner?

No. Official documents categorize Ciplar - LA as a nonselective beta-adrenergic receptor blocking agent, commonly referred to as a beta-blocker. It functions by moderating the effects of stress hormones and regulating circulatory function; it is not classified as a blood thinner (an anticoagulant).

Q: Is there a generic version of Ciplar - LA available?

Official regulatory listings confirm that the active ingredient, propranolol hydrochloride extended-release, is available in a non-branded, or generic, form. This indicates that a generic alternative exists for the brand-name product Ciplar - LA.

Q: What is the risk of dependence or addiction with Ciplar - LA?

Regulatory and government sources state that propranolol is not associated with a risk of physical dependence or addiction. However, official safety restrictions note that the abrupt discontinuation of the medicine can cause withdrawal symptoms.

Q: Can I take multivitamins or supplements while on Ciplar - LA?

Official drug interaction information indicates that certain minerals found in multivitamins or other supplements may decrease the absorption or overall effects of propranolol. Regulatory recommendations suggest separating the administration time of supplements and this medicine by at least two hours.

Q: Can Ciplar - LA affect cholesterol levels?

Official warnings and precautions for this class of medicine indicate that propranolol has been reported to cause changes in the body's lipid (cholesterol) profile. These changes may include increases in triglyceride levels and decreases in 'good' HDL cholesterol.

Q: Is the LA formulation better absorbed than the immediate-release tablet?

Pharmacokinetic data suggests that the active ingredient, propranolol, is highly absorbed by the body regardless of whether it is in the LA or standard form. The extended-release formulation is not designed for better absorption but rather for a slower and more consistent release over a full 24-hour period.

Q: Are there any specific foods or drinks to avoid when taking Ciplar - LA?

Official patient information includes a warning against alcohol consumption, as it may intensify certain side effects like dizziness or drowsiness. Regulatory documents also state that the medicine should be taken consistently with food intake—always with food or always on an empty stomach.

Q: Is Ciplar - LA safe for people with diabetes?

Official regulatory labeling describes that use is to be approached with caution in patients with diabetes. This is due to the potential for the medication to mask certain signs of low blood sugar (hypoglycemia), such as a rapid heart rate.

Q: Why might a doctor switch a patient from regular Ciplar to Ciplar - LA?

The primary intent behind the LA (extended-release) formulation is to enhance convenience and consistency of effect. Official product descriptions state that the LA design provides a continuous, 24-hour therapeutic effect with the convenience of only one dose per day, compared to the standard tablet, which needs to be taken multiple times daily.

Q: Is Ciplar - LA safe for elderly patients?

Official regulatory guidance indicates that a cautious approach is advised for older adults. Regulatory documents recommend that the medicine be initiated at the lower end of the dosing range and that any dose adjustments should be done gradually.

Q: Can Ciplar - LA be taken with acid reflux medication?

Regulatory drug interaction information lists that certain acid reflux medicines, such as cimetidine, may increase the concentration of propranolol in the blood. Because of this potential interaction, a doctor may need to adjust the propranolol dosage.

Q: What conditions does the FDA approve Ciplar - LA to treat?

According to the official Indications and Usage section, the extended-release capsule is approved for specific conditions. These formally documented uses include the treatment of high blood pressure, certain types of heart conditions (like angina), and the prevention of migraine headaches.

Q: What are the signs of an allergic reaction to Ciplar - LA?

Official regulatory labeling describes that signs of a serious adverse reaction may include rash, hives, swelling of the face, lips, tongue, or throat, and difficulty breathing. Serious adverse reactions are formally listed in official documents.

How should Ciplar - LA be stored and disposed of?

How to Store and Dispose of Ciplar - LA

Official regulatory guidelines define specific conditions to maintain the stability of propranolol hydrochloride extended-release capsules. The medication must be stored at controlled room temperature, specifically between 20^circC and 25^circC (68^circF to 77^circF). Storage must provide protection from light, excess heat, and moisture. It is required to keep the product in the container it came in and ensure the container remains tightly closed.

All medication must be stored out of the sight and reach of children.

For disposal of unused or expired capsules, a drug take-back program is the recommended method. If a program is unavailable, the product should be mixed with an undesirable substance (like coffee grounds), sealed in a container, and discarded in the household trash.

Ciplar - LA